Drug Profile
Mammastatin replacement therapy
Latest Information Update: 04 Jan 2007
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Biotherapies; M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer